The RECOVERY trial in the United Kingdom, a prospective, randomized and open study of dexamethasone steroid compared to previous care, concerned more than 6,000 coVID-19 patients. Dexamethasone reduced deaths through about a third in respirator patients and about one-fifth in other Americans who needed oxygen but were not on respirators. However, the study leaves questions about steroids to consider some patients.
“Our study is consistent with Britain’s promising results, but for the first time we are able to demonstrate that other Americans can see the critical benefits of angels with steroids compared to dexamethasone,” said Marlos Angeles Keller, MD, vice president of studies. Einstein and Montefiore Department of Medicine and a study leader. “We also found that a non-uncommon blood test can identify the ultimate productive applicants for steroid treatment.” Dr. Keller can also be a professor of medicine, obstetrics and gynecology and the physical condition of women at Einstein and an infectious disease specialist in Montefiore.